Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6Genitourinary 1

Conditions

Melanoma 6Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Ovarian Epithelial 5Breast Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Rectal Neoplasms 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms, Plasma Cell 3Multiple Myeloma 3Hodgkin Disease 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Burkitt Lymphoma 3Bile Duct Neoplasms 3Anus Neoplasms 3Waldenstrom Macroglobulinemia 2

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Melanoma × Interleukin-12 Subunit p35 × Clear all
NCT01307618 2016-10-24

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 8 charts
Dermatologic

Melanoma

NCT00003339 2014-05-22

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

University of Southern California

Phase 2 Completed
48 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00031733 2014-05-22

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

University of Southern California

Phase 2 Completed
60 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00002952 2013-09-05

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

University of Chicago

Phase 1/2 Completed
20 enrolled
Dermatologic

Melanoma

NCT00026143 2013-06-05

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
Dermatologic

Melanoma

NCT00004244 2013-03-21

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡